Our results demonstrate that EGCG inhibits IL-1β-induced uPAR expression by inhibiting ROS production and AP-1/NF-κB activation, and by decreasing cell invasion in T24 bladder cancer cells. This evidence concerns the gene FOS and urinary bladder carcinoma.